Lataa...
Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia
Therapy for acute myeloid leukemia (AML) involves intense cytotoxic treatment and yet approximately 70% of AML are refractory to initial therapy or eventually relapse. This is at least partially driven by the chemo-resistant nature of the leukemic stem cells (LSCs) that sustain the disease, and ther...
Tallennettuna:
| Julkaisussa: | Blood Cancer J |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Nature Publishing Group UK
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6889502/ https://ncbi.nlm.nih.gov/pubmed/29921955 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0087-2 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|